Closing the gap: Accelerating the translational process in nanomedicine by proposing standardized characterization techniques

International Journal of Nanomedicine

Volumn 9, Issue , 2014, Pages 5729-5751

  Khorasani, Ali A ^a   Weaver, James L ^b   Salvador Morales, Carolina ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Physicochemical characterization; Poly(ethylene glycol); Protein adsorption; Regulatory issues

Indexed keywords

NANOMATERIAL; PROTEIN;

ANALYTIC METHOD; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; GOVERNMENT; HUMAN; INDUSTRY; LEGAL ASPECT; MEDICAL RESEARCH; MOLECULAR INTERACTION; NANOANALYSIS; NANOMEDICINE; STANDARD; STANDARDIZATION; CHEMISTRY; MATERIALS TESTING; PHYSICAL CHEMISTRY; PROCEDURES; STANDARDS; TRANSLATIONAL RESEARCH;

HUMANS; MATERIALS TESTING; NANOMEDICINE; NANOSTRUCTURES; PHYSICOCHEMICAL PHENOMENA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84931059746     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S72479     Document Type: Article

References (132)

1. Executive Offce of the President of the United States. The National Nanotechnology Initiative Supplement to the President’s 2015 Budget. Washington, DC, USA: National Science and Technology Council; 2014. Available from: http://www.whitehouse.gov/sites/default/fles/microsites/ostp/NNI_FY15_Final.pdf. Accessed October 3, 2014.
2. Roko MC, Mirkin CA, Hersam MC. WTEC panel report on nanotechnology research directions for societal needs in 2020: retrospective and outlook. Washington, DC, USA: World Technology Evaluation Center Inc; 2010. Available from: http://www.wtec.org/nano2/Nanotechnology_Research_Directions_to_2020/. Accessed October 3, 2014.
3. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
4. Rodriguez F, Cohen C, Ober CK, Archer LA. Molecular weight distribution and average molecular weight. Principles of Polymer Systems. 5th ed. New York, NY, USA: Taylor and Francis Books Inc; 2003.
5. Clogston J, Patri AK. Importance of physicochemical characterization prior to immunological studies. In: Dobrovolskaia MA, McNeil SE, editors. Handbook of Immunological Properties of Engineered Nanomaterials. Volume 1. Hackensack, NJ, USA: World Scientifc Publishing; 2012.
6. Ehmann HM, Spirk S, Doliška A, et al. Generalized indirect fourier transformation as a valuable tool for the structural characterization of aqueous nanocrystalline cellulose suspensions by small angle x-ray scattering. Langmuir. 2013;29(11):3740–3748.
7. Sadana A. Protein adsorption and inactivation on surfaces. Influence of heterogeneities. Chem Rev. 1992;92(8):1799–1818.
8. Linkov P, Artemyev M, Efmov AE, Nabiev I. Comparative advantages and limitations of the basic metrology methods applied to the characterization of nanomaterials. Nanoscale. 2013;5(19):8781–8798.
9. Salvador-Morales C, Valencia PM, Gao W, Karnik R, Farokhzad OC. Spontaneous formation of heterogeneous patches on polymer-lipid core-shell particle surfaces during self-assembly. Small. 2013;9(4):511–517.
10. Roh KH, Martin DC, Lahann J. Biphasic Janus particles with nanoscale anisotropy. Nat Mater. 2005;4(10):759–763.
11. Roh KH, Martin DC, Lahann J. Triphasic nanocolloids. J Am Chem Soc. 2006;128(21):6796–6797.
12. Mullen DG, Banaszak Holl MM. Heterogeneous ligand-nanoparticle distributions: a major obstacle to scientific understanding and commercial translation. Acc Chem Res. 2011;44(11):1135–1145.
13. McPhail MR, Sells JA, He Z, Chusuei CC. Charging nanowalls: adjusting the carbon nanotube isoelectric point via surface functional-ization. J Phys Chem C. 2009;113(32):14102–14109.
14. Florea I, Ersen O, Arenal R, et al. 3D analysis of the morphology and spatial distribution of nitrogen in nitrogen-doped carbon nanotubes by energy-fltered transmission electron microscopy tomography. J Am Chem Soc. 2012;134(23):9672–9680.
15. RISE Microscopy: Correlative Raman SEM Imaging – WITec: Focus Innovations. Available from: http://www.witec.de/products/raman/ rise-microscopy/. Accessed July 3, 2014.
16. Heckel JC, Kisley LM, Mannion JM, Chumanov G. Synthesis and self-assembly of polymer and polymer-coated Ag nanoparticles by the reprecipitation of binary mixtures of polymers. Langmuir. 2009;25(17):9671–9676.
17. Shah AA, Schultz B, Kohlstedt KL, Glotzer SC, Solomon MJ. Synthesis, assembly, and image analysis of spheroidal patchy particles. Langmuir. 2013;29(15):4688–4696.
18. Arora S, Rajwade JM, Paknikar KM. Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol. 2012;258(2): 151–165.
19. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev. 2012;112(11):5818–5878.
20. Valencia PM, Hanewich-Hollatz MH, Gao W, et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials. 2011;32(26):6226–6233.
21. Gomes R, Roming S, Przybilla A, Meier MAR, Feldmann C. Barium peroxide nanoparticles: synthesis, characterization and their use for actuating the luminol chemiluminescence. J Mater Chem C. 2014;2(8): 1513–1518.
22. Kazarian SG, Chan KLA, Tay FH. ATR-FT-IR Imaging for Pharmaceutical and Polymeric Materials: From Micro to Macro Approaches. In: Salzer R, Siesler HW, editors. Infrared and Raman Spectroscopic Imaging. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2009:347–375.
23. Liu H, Webster TJ. Nanomedicine for implants: a review of studies and necessary experimental tools. Biomaterials. 2006;28(2):354–369.
24. Mudunkotuwa IA, Minshid AA, Grassian VH. ATR-FTIR spectroscopy as a tool to probe surface adsorption on nanoparticles at the liquid-solid interface in environmentally and biologically relevant media. Analyst. 2014;139(5):870–881.
25. Sundaram S, Sacksteder CA, Weber TJ, et al. Fourier-transform infrared spectroscopy for rapid screening and live-cell monitoring: application to nanotoxicology. Nanomedicine (Lond). 2013;8(1):145–156.
26. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials. 2011; 32(28):6791–6803.
27. Lin P, Lin CW, Mansour R, Gu F. Improving biocompatibility by surface modifcation techniques on implantable bioelectronics. Biosens Bioelectron. 2013;47:451–460.
28. Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials. 2013;34(4):1213–1222.
29. Fregnaux M, Gaumet JJ, Dalmasso S, Laurenti JP, Schneider R. Mass spectrometry techniques in the context of nanometrology. Microelectron Eng. 2013;108:187–191.
30. Bednar AJ, Poda AR, Mitrano DM, et al. Comparison of on-line detectors for feld fow fractionation analysis of nanomaterials. Talanta. 2013;104:140–148.
31. Laborda F, Bolea E, Jiménez-Lamana J. Single particle inductively coupled plasma mass spectrometry: a powerful tool for nanoanalysis. Anal Chem. 2013;86(5):2270–2278.
32. Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A. 2007;104(7): 2050–2055.
33. Mochalov KE, Efmov AE, Bobrovsky A, et al. Combined scanning probe nanotomography and optical microspectroscopy: a correlative technique for 3D characterization of nanomaterials. ACS Nano. 2013; 7(10):8953-8962.
34. Baer DR, Gaspar DJ, Nachimuthu P, Techane SD, Castner DG. Application of surface chemical analysis tools for characterization of nanoparticles. Anal Bioanal Chem. 2010;396(3):983–1002.
35. Sitterberg J, Oezcetin A, Ehrhardt C, Bakowsky U. Utilising atomic force microscopy for the characterisation of nanoscale drug delivery systems. Eur J Pharm Biopharm. 2010;74(1):2–13.
36. Pekarek KJ, Jacob JS, Mathiowitz E. Double-walled polymer microspheres for controlled drug release. Nature. 1994;367(6460):258–260.
37. Xiao CD, Shen XC, Tao L. Modifed emulsion solvent evaporation method for fabricating core–shell microspheres. Int J Pharm. 2013; 452(1–2):227–232.
38. Jin-Phillipp NY, Krauss TN, van Aken PA. The growth of one-dimensional CuPcF16 nanostructures on gold nanoparticles as studied by transmission electron microscopy tomography. ACS Nano. 2012;6(5):4039–4044.
39. Sharma R, Bisen DP, Shukla U, Sharma BG. X-ray diffraction: a powerful method of characterizing nanomaterials. Recent Research in Science and Technology. 2012;4(8):77–79. Available from: http://recent-science.com/index.php/rrst/article/viewFile/14887/7589. Accessed October 3, 2014.
40. Bóta A. Development of powder diffraction apparatus for small-angle X-ray scattering measurements. J Appl Crystallogr. 2013;46(2): 573–576.
41. Renaud G, Lazzari R, Leroy F. Probing surface and interface morphology with grazing incidence small angle X-ray scattering. Surf Sci Rep. 2009;64(8):255–380.
42. Gouadec G, Colomban P. Raman spectroscopy of nanostructures and nanosized materials. J Raman Spectrosc. 2007;38(6):598–603.
43. Kiefer W. Recent advances in linear and nonlinear Raman spectros-copy II. J Raman Spectrosc. 2008;39(12):1710–1725.
44. Arora AK, Rajalakshmi M, Ravindran TR, Sivasubramanian V. Raman spectroscopy of optical phonon confnement in nanostructured materials. J Raman Spectrosc. 2007;38(6):604–617.
45. Rolo AG, Vasilevskiy MI. Raman spectroscopy of optical phonons confned in semiconductor quantum dots and nanocrystals. J Raman Spectrosc. 2007;38(6):618–633.
46. Bhaskar S, Gibson CT, Yoshida M, et al. Engineering, characterization and directional self-assembly of anisotropically modifed nanocolloids. Small. 2011;7(6):812–819.
47. Llop J, Estrela-Lopis I, Ziolo RF, et al. Uptake, biological fate, and toxicity of metal oxide nanoparticles. Part Part Syst Char. 2014;31(1): 24–35.
48. Andrade N, Martinez D, Paula A, Silveira J, Alves O, Souza Filho A. Temperature effects on the nitric acid oxidation of industrial grade multiwalled carbon nanotubes. J Nanopart Res. 2013;15(7):1–11.
49. Haase A, Tentschert J, Jungnickel H, et al. Toxicity of silver nanoparticles in human macrophages: uptake, intracellular distribution and cellular responses. J Phys Conf Ser. 2011;304(1):012030.
50. Romero G, Estrela-Lopis I, Zhou J, et al. Surface engineered poly(lactide-co-glycolide) nanoparticles for intracellular delivery: uptake and cytotoxicity – a confocal Raman microscopic study. Biomac-romolecules. 2010;11(11):2993–2999.
51. Buyens K, De Smedt SC, Braeckmans K, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release. 2012;158(3): 362–370.
52. Sugiyama I, Sadzuka Y. Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes. Curr Drug Discov Technol. 2011;8(4):357–366.
53. Allen C, Dos Santos N, Gallagher R, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep. 2002;22(2):225–250.
54. Salvador-Morales C, Zhang L, Langer R, Farokhzad OC. Immu-nocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009; 30(12):2231–2240.
55. Fukushima K, Hedrick JL, Nelson A, Sanders DP, inventors; International Business Machines Corporation, USA, assignee. Surface modifed nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery. US Patent US20110182996A12011.
56. Horcajada P, Chalati T, Serre C, et al. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater. 2010;9(2):172–178.
57. Horcajada Cortes P, Ferey G, Serre C, Gref R, Couvreur P, inventors; Centre National de la Recherche Scientifque – CNRS, Fr; Universite de Versailles Saint-Quentin-en-Yvelines, assignee. Organic-inorganic hybrid solid with a modified surface. US Patent WO2009077671A12009.
58. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev. 2009;61(10):768–784.
59. Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm. 2007;66(3):303–317.
60. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv. 2006;3(1):139–162.
61. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273–1289.
62. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev. 2002;54(2): 235–252.
63. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54(2):169–190.
64. Ren J, Shen S, Wang D, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012;33(11):3324–3333.
65. Cheng J, Meziani MJ, Sun YP, Cheng SH. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an effcient drug carrier for overcoming multidrug resistance. Toxicol Appl Pharmacol. 2011; 250(2):184–193.
66. Bhirde AA, Patel S, Sousa AA, et al. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond). 2010;5(10):1535–1546.
67. Liu Z, Sun X, Nakayama-Ratchford N, Dai H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano. 2007;1(1):50–56.
68. Angelini G, Boncompagni S, De Maria P, et al. Layer-by-layer deposition of shortened nanotubes or polyethylene glycol-derivatized nanotubes on liposomes: a tool for increasing liposome stability. Carbon. 2007;45(13):2479–2485.
69. Graham NB. Introduction to biotechnical and biomedical applications of poly(ethylene glycol). In: Harris JM, editor. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. New York, NY, USA: Plenum Press; 1992.
70. Mosqueira VC, Legrand P, Gulik A, et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials. 2001;22(22):2967–2979.
71. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano. 2010;4(11):6629–6638.
72. Graham NB. Poly(ethylene glycol) gels and drug delivery. In: Harris JM, editor. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. New York, NY, USA: Plenum Press; 1992.
73. Gref R, Lück M, Quellec P, et al. ‘Stealth’ corona-core nanoparticles surface modifed by polyethylene glycol (PEG): infuences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3–4):301–313.
74. Bailey FE Jr. Poly(ethylene oxide). Maryland Heights, MO, USA: Elsevier; 2012.
75. Deng L, Zhang Y, Ma L, et al. Comparison of anti-EGFR-Fab’ conjugated immunoliposomes modifed with two different conjugation linkers for siRNA delivery in SMMC-7721 cells. Int J Nanomedicine. 2012;8:3271–3283.
76. Hansen CM. Hansen Solubility Parameters: A User’s Handbook. Boca Raton, FL, USA: CRC Press; 2012.
77. Rodriguez F, Cohen C, Ober CK, Archer LA. Viscous flow. In: Principles of Polymer Systems. 5th ed. New York, NY, USA: Taylor and Francis Books Inc; 2003.
78. Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30(8):1627–1634.
79. Shi J, Xiao Z, Vilos C, Votruba A, Langer RS, Farokhzad OC. Lipid-polymer hybrid particles. Google Patents; 2011.
80. Zhang L, He Y, Ma G, Song C. Preparation, characterization and in vitro and in vivo studies on folate-targeted biodegradable polymersomes loaded with paclitaxel. Zhongguo Zhong Yao Za Zhi. 2010;45(22):1742–1748. Chinese.
81. Farokhzad OC, Salvador-Morales C, Gao W, Zhang L, Chen JM, Langer RS, inventors; Brigham and Women’s Hospital Inc, USA; Massachusetts Institute of Technology, assignee. Particles with multiple functionalized surface domains for controlled and sustained drug release. US Patent WO2010042555A22010.
82. Feng G, Ding D, Li K, Liu J, Liu B. Reversible photoswitching conjugated polymer nanoparticles for cell and ex vivo tumor imaging. Nanoscale. 2014;6(8):4141–4147.
83. Riley T, Heald CR, Stolnik S, et al. Core-shell structure of PLA-PEG nanoparticles used for drug delivery. Langmuir. 2003;19(20): 8428–8435.
84. Milani S, Bombelli FB, Pitek AS, Dawson KA, Rädler J. Reversible versus irreversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano. 2012;6(3): 2532–2541.
85. Mahmoudi M, Saeedi-Eslami SN, Shokrgozar MA, et al. Cell “vision”: complementary factor of protein corona in nanotoxicology. Nanoscale. 2012;4(17):5461–5468.
86. Andersson J, Ekdahl KN, Lambris JD, Nilsson B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials. 2005;26(13): 1477–1485.
87. Zeng S, Huang YM, Chang CE, Zhong W. Protein binding for detection of small changes on a nanoparticle surface. Analyst. 2014; 139(6):1364–1371.
88. Treuel L, Brandholt S, Maffre P, Wiegele S, Shang L, Nienhaus GU. Impact of protein modifcation on the protein corona on nanoparticles and nanoparticle-cell interactions. ACS Nano. 2014;8(1):503–513.
89. Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release. 2013;166(2):182–194.
90. Wei A, Mehtala JG, Patri AK. Challenges and opportunities in the advancement of nanomedicines. J Control Release. 2012;164(2): 236–246.
91. Zasadzinski JA, Stenger PC, Shieh I, Dhar P. Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability. Biochim Biophys Acta. 2010;1798(4): 801–828.
92. Tcholakova S, Denkov ND, Sidzhakova D, Ivanov IB, Campbell B. Effects of electrolyte concentration and pH on the coalescence stability of β-lactoglobulin emulsions: experiment and interpretation. Langmuir. 2005;21(11):4842–4855.
93. Kwon MJ, Lee J, Wark AW, Lee HJ. Nanoparticle-enhanced surface plasmon resonance detection of proteins at attomolar concentrations: comparing different nanoparticle shapes and sizes. Anal Chem. 2012;84(3):1702–1707.
94. Kristensen SH, Pedersen GA, Nejsum LN, Sutherland DS. Protein adsorption at nanopatterned surfaces studied by quartz crystal microbalance with dissipation and surface plasmon resonance. J Phys Chem B. 2013;117(36):10376–10383.
95. Ohtsuki C, Ichikawa Y, Shibata H, Kawachi G, Torimoto T, Ogata S. Sensing of protein adsorption with a porous bulk composite comprising silver nanoparticles deposited on hydroxyapatite. J Mater Sci Mater Med. 2010;21(4):1225–1232.
96. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481–503.
97. Pio R, Ajona D, Lambris JD. Complement inhibition in cancer therapy. Semin Immunol. 2013;25(1):54–64.
98. Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ, Minchin RF. Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano. 2014;8(4): 3357–3366.
99. Arnida Malugin A, Ghandehari H. Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J Appl Toxicol. 2010;30(3):212–217.
100. Wang HJ, Cao Y, Sun YY, et al. Is there an optimal topographical surface in nanoscale affecting protein adsorption and cell behaviors? J Nanopart Res. 2011;13(9):4201–4210.
101. Wang HJ, Sun YY, Cao Y, et al. Is there an optimal topographical surface in nano-scale affecting protein adsorption and cell behaviors? Part II. J Nanopart Res. 2012;14(5):1–10.
102. Gon S, Santore MM. Sensitivity of protein adsorption to architectural variations in a protein-resistant polymer brush containing engineered nanoscale adhesive sites. Langmuir. 2011;27(24):15083–15091.
103. Hentschel C, Wagner H, Smiatek J, et al. AFM-based force spectroscopy on polystyrene brushes: effect of brush thickness on protein adsorption. Langmuir. 2013;29(6):1850–1856.
104. Gessner A, Lieske A, Paulke BR, Muller RH. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm. 2002;54(2):165–170.
105. Gessner A, Waicz R, Lieske A, Paulke BR, Mader K, Muller RH. Nanoparticles with decreasing surface hydrophobicities: infuence on plasma protein adsorption. Int J Pharm. 2000;196(2):245–249.
106. Lück M, Paulke BR, Schröder W, Blunk T, Müller RH. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res. 1998;39(3):478–485.
107. Paulke BR, Moeglich PM, Knippel E, Budde A, Nitzche R, Muller RH. Electrophoretic 3D-mobility profles of latex particles with different surface groups. Langmuir. 1995;11(1):70–74.
108. Norde W. Surface-tethered polymers to infuence protein adsorption and microbial adhesion. Z Phys Chem (N F). 2007;221(1):47–63.
109. Ma N, Ma C, Li C, et al. Infuence of nanoparticle shape, size, and surface functionalization on cellular uptake. J Nanosci Nanotechnol. 2013;13(10):6485–6498.
110. Yezek L. Surfactant Adsorption on Colloids: Studies Using the Electro-phoretic Fingerprinting Approach. In: Somasundaran, P, editor. Encyclopedia of Surface and Colloid Science. 2nd ed. 2006:6048–6055.
111. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012;41(7):2780–2799.
112. Imaz A, Ramos J, Forcada J. Surface functionalization of latex particles. In: Hidalgo-Alvarez R, editor. Structure and Functional Properties of Colloidal Systems. Boca Raton, FL, USA: CRC Press; 2009.
113. Oehlke K, Adamiuk M, Behsnilian D, et al. Potential bioavailability enhancement of bioactive compounds using food-grade engineered nanomaterials: a review of the existing evidence. Food Funct. 2014;5(7):1341–1359.
114. Bancos S, Tyner KM, Weaver JL. Immunotoxicity testing for drug-nano-particle conjugates: regulatory considerations. In: Dobrovolskaia MA, McNeil SE, editors. Handbook of Immunological Properties of Engineered Nanomaterials. Volume 1. Hackensack, NJ, USA: World Scientifc Publishing Co; 2013.
115. Mérian J, Boisgard R, Decleves X, Thezé B, Texier I, Tavitian B. Synthetic lipid nanoparticles targeting steroid organs. J Nucl Med. 2013;54(11):1996–2003.
116. Singh S, Sharma A, Robertson GP. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res. 2012;72(22):5663–5668.
117. Simkó M, Nosske D, Kreyling W. Metrics, dose, and dose concept: the need for a proper dose concept in the risk assessment of nanoparticles. Int J Environ Res Public Health. 2014;11(4):4026–4048.
118. Cohen JM, Teeguarden JG, Demokritou P. An integrated approach for the in vitro dosimetry of engineered nanomaterials. Part Fibre Toxicol. 2014;11(1):20.
119. Sauer UG, Vogel S, Aumann A, et al. Applicability of rat precision-cut lung slices in evaluating nanomaterial cytotoxicity, apoptosis, oxidative stress, and inflammation. Toxicol Appl Pharmacol. 2014;276(1):1–20.
120. Donaldson K, Schinwald A, Murphy F, et al. The biologically effective dose in inhalation nanotoxicology. Acc Chem Res. 2012;46(3): 723–732.
121. Vernon JA, Golec JH, Dimasi JA. Drug development costs when fnancial risk is measured using the Fama-French three-factor model. Health Econ. 2010;19(8):1002–1005.
122. US Food and Drug Administration. Code of Federal Regulations Title 21. Silver Spring, MD, USA: US Department of Human and Health Services; 2013. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.122. Accessed October 3, 2014.
123. US Food and Drug Administration. Guidance for Industry: CGMP for Phase 1 Investigational Drugs. In: US Department of Human and Health Services. Rockville, MD, USA: Offce of Training and Communication, Division of Drug information, Center for Drug Evaluation and Research, Food and Drug Administration; 2008. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070273.pdf. Accessed October 3, 2014.
124. Tyner K, Sadrieh N. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. In: McNeil SE, editor. Characterization of Nanoparticles Intended for Drug Delivery. Totowa, NJ, USA: Humana Press; 2011.
125. Baraldi G, Carrada M, Toudert J, et al. Preventing the degradation of Ag nanoparticles using an ultrathin a-Al2O3 layer as protective barrier. J Phys Chem C. 2013;117(18):9431–9439.
126. Ramos J, Forcada J, Hidalgo-Alvarez R. Cationic polymer nanoparticles and nanogels: from synthesis to biotechnological applications. Chem Rev. 2014;114(1):367–428.
127. Richardson SD, Ternes TA. Water analysis: emerging contaminants and current issues. Anal Chem. 2014;86(6):2813–2848.
128. Zolnik BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev. 2009;61(6):422–427.
129. Gebel T, Marchan R, Hengstler JG. The nanotoxicology revolution. Arch Toxicol. 2013;87(12):2057–2062.
130. Klaper R, Arndt D, Bozich J, Dominguez G. Molecular interactions of nanomaterials and organisms: defning biomarkers for toxicity and high-throughput screening using traditional and next-generation sequencing approaches. Analyst. 2014;139(5):882–895.
131. Setyawati MI, Fang W, Chia SL, Leong DT. Nanotoxicology of common metal oxide based nanomaterials: their ROS-y and non-ROS-y consequences. Asia-Pacific Journal of Chemical Engineering. 2013;8(2):205–217.
132. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004;11(3):169–183.